1. Home
  2. PCSA vs WTO Comparison

PCSA vs WTO Comparison

Compare PCSA & WTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCSA
  • WTO
  • Stock Information
  • Founded
  • PCSA 2011
  • WTO 2008
  • Country
  • PCSA United States
  • WTO China
  • Employees
  • PCSA 13
  • WTO N/A
  • Industry
  • PCSA Biotechnology: Pharmaceutical Preparations
  • WTO Consumer Electronics/Appliances
  • Sector
  • PCSA Health Care
  • WTO Technology
  • Exchange
  • PCSA Nasdaq
  • WTO Nasdaq
  • Market Cap
  • PCSA 3.3M
  • WTO 3.3M
  • IPO Year
  • PCSA N/A
  • WTO 2021
  • Fundamental
  • Price
  • PCSA $0.22
  • WTO $0.92
  • Analyst Decision
  • PCSA Strong Buy
  • WTO
  • Analyst Count
  • PCSA 1
  • WTO 0
  • Target Price
  • PCSA $6.00
  • WTO N/A
  • AVG Volume (30 Days)
  • PCSA 46.5M
  • WTO 66.5K
  • Earning Date
  • PCSA 08-12-2025
  • WTO 07-29-2025
  • Dividend Yield
  • PCSA N/A
  • WTO N/A
  • EPS Growth
  • PCSA N/A
  • WTO N/A
  • EPS
  • PCSA N/A
  • WTO N/A
  • Revenue
  • PCSA N/A
  • WTO $32,309,502.00
  • Revenue This Year
  • PCSA N/A
  • WTO N/A
  • Revenue Next Year
  • PCSA N/A
  • WTO N/A
  • P/E Ratio
  • PCSA N/A
  • WTO N/A
  • Revenue Growth
  • PCSA N/A
  • WTO 47.36
  • 52 Week Low
  • PCSA $0.15
  • WTO $0.75
  • 52 Week High
  • PCSA $3.10
  • WTO $622.50
  • Technical
  • Relative Strength Index (RSI)
  • PCSA 44.28
  • WTO 39.41
  • Support Level
  • PCSA $0.20
  • WTO $0.75
  • Resistance Level
  • PCSA $0.33
  • WTO $1.06
  • Average True Range (ATR)
  • PCSA 0.09
  • WTO 0.08
  • MACD
  • PCSA -0.01
  • WTO 0.03
  • Stochastic Oscillator
  • PCSA 6.53
  • WTO 51.61

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

About WTO UTime Limited

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; and Do, as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

Share on Social Networks: